Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new revision tag v3.5.4 was added to the page’s revision history, replacing v3.5.3. This reflects an update to the document’s versioning without altering its substantive content.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe page’s footer shows an updated site/application revision from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check43 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed. This appears to be a minor site maintenance update that does not alter the page content.SummaryDifference0.1%

- Check80 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. No visible changes to study details, eligibility criteria, or results content.SummaryDifference0.1%

- Check87 days agoChange DetectedFooter area now includes labels/links for 'Moffitt Cancer Center Clinical Trials website' and 'H. Lee Moffitt Cancer Center and Research Institute' along with a 'Helpful Links Provided by' note.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.